LumiraDx Investor Presentation Deck

1 Unmet Need for High Sensitivity Troponin POC Test with a $900M Addressable Market(1) Intended Use Regulatory Authorization LOQ Clinical Sensitivity Reportable Range Sample Size Sample Type Time to Result lumiraDx™ True POC Needs Aids in diagnosis of MI CE Mark, FDA 510K s2.0 ng/L I Whole blood (2h): 90% + 2.0 – 1,000 ng/L 20μL direct fingerstick | Capillary WB, venous blood, plasma ≤10 min Lab Reference Abbott Architect STAT hs-Tnl* Aids in diagnosis of MI CE Mark, FDA 510K ≤3.2 ng/L (specification) 1.5-2.9 ng/L (observed) EDTA Plasma (2-4h): 90.9% 3.2 – 50,000 ng/L 210 µL (on-board) 10 μL (manual dilution) Plasma & serum (LiHep, EDTA) 18 min (time to first result) POC Example Siemens Atellica VTLi hs-cTnl* Aids in diagnosis of MI CE Mark 2.1 ng/L plasma 3.7 ng/L - WB Whole blood (2h): 81.3% 2.1 (plasma)/3.7 (WB) - 1,250 ng/L 30-100 µL Capillary WB, venous WB & plasma (LiHep) Copyright © 2022 Luminox Ltd. All Rights Reserved, Worldwide 8 min (1) Based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC, and (c) expansion of diagnostic testing. (2) Based on respective company product specifications. POC Example Triage True hsTnl(2) Aids in diagnosis of MI CE Mark 2.1-3.6 ng/L - plasma 2.8 ng/L - WB EDTA Plasma (2-4h): 91.9% 0.1 – 1,000 ng/L 175 µL Venous WB & plasma (EDTA) 20 min Key differentiator 27

View entire presentation